Stephens Alick C
Imperial College London, Department of Paediatrics, Faculty of Medicine, 2nd Floor Medical School, St Mary's Campus, Norfolk Place, Paddington London, W2 1PG UK.
Curr Opin Mol Ther. 2004 Oct;6(5):551-8.
AVI BioPharma is developing AVI-4126, an antisense oligonucleotide targeted to c-myc mRNA for the potential treatment of restenosis, cancer and polycystic kidney disease. AVI-4126 is currently undergoing phase II clinical trials.
AVI生物制药公司正在研发AVI-4126,这是一种针对c-myc信使核糖核酸的反义寡核苷酸,用于潜在治疗再狭窄、癌症和多囊肾病。AVI-4126目前正在进行二期临床试验。